Cosmetic composition for improving skin conditions comprising totarol or dipropylene glycol

Abstract

The present invention relates to a cosmetic composition, the cosmetic composition according to one aspect exhibits sebum inhibiting, pore shrinking, blackhead improving, and skin improving effects by including totarol and dipropylene glycol, DPG, and the cosmetic composition can be used as a cosmetic for improving the overall skin condition.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to and the benefit of Korean Patent Application No. 10-2023-0100042, filed on Jul. 31, 2023, which is hereby incorporated by reference for all purposes as if fully set forth herein. Technical Field

[0003] The present invention relates to a cosmetic composition. Background Art

[0004] "Totarol" is one of the diterpenoid compounds extracted from Podocarpus totara of the genus Podocarpus, and is known as an antioxidant, deodorant, etc., and is used as an ingredient of cosmetics, toothpaste, and the like.

[0005] Blackheads are caused by excessive sebum, residue, keratin and other substances binding to the inner wall of the pores, which cause the pores to become clogged. When these substances reach the opening of the pores on the surface of the skin, they are oxidized and turn black. This is especially common in oily areas such as the T-zone including the forehead, nose and chin. Blackheads may appear alone without other kinds of skin problems, or they may appear together with acne.

[0006] In order to remove these blackheads, it is important to inhibit the production of excessive oil or sebum or promote the discharge of black bodies from the pores, and remove the old keratin that does not disappear naturally on the skin. However, once blackheads are formed, it is difficult for the widened pores to shrink again, so blackheads are easily formed again, which becomes a cause of difficulty in management.

[0007] The inventors of the present invention have completed the present invention by confirming that when totarol is treated alone or totarol and a dipropylene glycol (DPG) solvent are treated together, there is a synergistic effect in lipid synthesis inhibition and antibacterial activity. Therefore, the composition of the present invention including totarol and DPG can be used as a cosmetic for inhibiting sebum, shrinking pores, improving blackheads and improving skin quality. Summary of the invention

[0008] One aspect provides a cosmetic composition for improving skin condition, comprising totarol.

[0009] Another aspect provides a skin external preparation composition for improving skin conditions, comprising totarol.

[0010] One aspect provides a cosmetic composition for the skin condition, which includes totarol. In addition to totarol, the cosmetic composition is characterized by additionally including a polyol.

[0011] The term "totarol" in the present specification is one of diterpenes, which is a compound having a structure represented by the following Chemical Formula 1, and is known as an antioxidant, a deodorant, or the like.

[0012]

[0013] The totarol of the present invention may be a product extracted from Podocarpus totara of the genus Podocarpus or a product obtained by chemical synthesis, but is not limited thereto.

[0014] In one embodiment, the totarol can be one or more selected from the group consisting of dipropylene glycol, neopentyl glycol, diglycerol, glycerol, 1,3-butylene glycol, propylene glycol, propane diol, methyl propane diol, butylene glycol and sorbitol, but specifically can be dipropylene glycol.

[0015] The term "dipropylene glycol (DPG)" in this specification is a mixture of 4-hydroxy-2,6-hexanediol, 2-(2-hydroxypropoxy)-1-propanol, and 2-(2-hydroxy-1-methyl-ethoxy)-1-propanol, which exists in the form of a colorless transparent liquid and is known as a fragrance, solvent, viscosity reducer, etc.

[0016] Relative to 100 parts by weight of the entire cosmetic composition of the present invention, the content of totarol and dipropylene glycol can be 0.0001 to 99.9 parts by weight, specifically, 0.0001 to 90 parts by weight, 0.0001 to 80 parts by weight, 0.0001 to 60 parts by weight, 0.0001 to 40 parts by weight, 0.0001 to 20 parts by weight, 0.0001 to 10 parts by weight, 0.001 to 80 parts by weight, 0.001 to 60 parts by weight, 0.001 to 40 parts by weight. Part by weight, 0.001 to 20 parts by weight, 0.001 to 10 parts by weight, 0.01 to 60 parts by weight, 0.01 to 40 parts by weight, 0.01 to 20 parts by weight, 0.01 to 10 parts by weight, 0.01 to 5 parts by weight, 0.01 to 3 parts by weight, 0.01 to 1 part by weight, 0.1 to 20 parts by weight, 0.1 to 10 parts by weight, 0.1 to 5 parts by weight, 0.01 to 3 parts by weight, 0.1 to 1 part by weight, or 0.1 to 0.5 parts by weight, but is not particularly limited thereto.

[0017] In one embodiment, it was confirmed that when totarol and dipropylene glycol solvent were treated together, when the concentration exceeded 0.01% (1 ppm of totarol), it was cytotoxic ( Figure 6). Therefore, in the cosmetic composition for improving skin conditions including totarol and polyol, the content of totarol may be 0.001 to 0.01 parts by weight relative to 100 parts by weight of the entire cosmetic composition.

[0018] The term "improving skin condition" in the present specification may refer to one or more selected from the group consisting of inhibiting sebum, shrinking pores, improving blackheads, and improving skin quality. Specifically, the "sebum inhibition" may refer to any behavior of reducing the production and discharge of oil or sebum in skin pores by inhibiting the expression of enzymes involved in lipid synthesis such as SREBP-1a, the "shrinking pores" and "improving blackheads" may refer to any behavior of reducing pore size or inhibiting the production of blackheads in pores by inhibiting the production and discharge of sebum and inhibiting oxidation by the composition of the present invention, and the "improving skin quality" may refer to any behavior of improving skin problems such as skin keratinization and inflammation by inhibiting sebum and antibacterial activity of the composition of the present invention, thereby smoothing the skin quality.

[0019] In one embodiment, it was confirmed that when totarol was treated alone (totarol 1 ppm) or totarol and dipropylene glycol solvent were treated together (0.01%, totarol 1 ppm), the mRNA expression of the enzyme (SREBP-1a) involved in lipid synthesis was significantly inhibited, and there was a synergistic effect in inhibiting lipid synthesis ( Figure 2 and Figure 3 ). In addition, in one embodiment, it was confirmed that when totarol and dipropylene glycol solvent were treated together, the antibacterial effect on Staphylococcus aureus and Propionibacterium Acnes was increased compared with the case where totarol was treated alone ( Figure 4 and Figure 5 ).

[0020] The dosage form of the cosmetic composition can be a solution, an external ointment, an emulsion, a cream, a foam, a nutritious lotion, a softening lotion, a perfume, a facial mask, a softening water, a lotion, a base makeup, an essence, a soap, a liquid cleanser, a bath salt, a sunscreen, a sun oil, a suspension, an emulsion, a paste, a lotion, a powder, a surfactant-containing cleanser, an oil, a foundation, an emulsion foundation, a wax foundation, a patch or a spray, but is not particularly limited thereto. Specifically, the dosage form of the cosmetic composition can be any one selected from the group consisting of an emulsion, a cream, a lotion, a solution, a suspension, a gel, a patch, a sheet mask, a film, a paste, a spray, a foam and clean water.

[0021] The cosmetic composition may additionally include functional additives and ingredients included in general cosmetic compositions, and may further include commonly used auxiliary ingredients and carriers, such as commonly used antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, etc. For example, the cosmetic composition may further include auxiliary ingredients such as glycerin, butylene glycol, ethoxylated hydrogenated castor oil, tocopheryl acetate, citric acid, squalane, sodium citrate, and allantoin, etc., and as a solvent, may include hexylene glycol and purified water, etc.

[0022] In addition, as functional additives, it can include a group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular peptides, high molecular polysaccharides, sphingolipids and seaweed extracts. As mixed ingredients included in addition, it can include oil components, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohol, pigments, fragrances, blood circulation promoters, cooling agents, antiperspirants, and purified water, but is not particularly limited to these.

[0023] On the other hand, a skin topical composition for improving skin condition is provided, which includes totarol. The same parts as above also apply to the skin topical composition. In addition, the skin topical composition is characterized in that it additionally includes dipropylene glycol in addition to totarol.

[0024] The skin preparation can be a cream, a gel, an ointment skin emulsifier, a skin suspension, a transdermal delivery patch, a medicated bandage, a lotion, or a combination thereof. As required, the skin preparation can be appropriately mixed with ingredients used in skin preparations of general cosmetics or pharmaceuticals, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or a combination thereof.

[0025] The skin external preparation can also be appropriately mixed with metal chelating agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate and gluconic acid, caffeine, tannin, verapamil, licorice extract, glabridin, hot water extract of Carin fruit, various crude drugs, tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts, vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside, arbutin, kojic acid, glucose, fructose, trehalose and other sugars. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1The results of confirming the stability of totarol according to each solvent over a period of 4 weeks are shown. The stability confirmation conditions were performed at low temperature (Ref, 4°C), normal temperature (RT), high temperature (HT, 55°C) and sunlight (SUN).

[0027] Figure 2 The results confirming the lipid synthesis inhibitory effect of totarol alone or in combination with DPG are shown.

[0028] Figure 3 A and B show the results of confirming the lipid synthesis inhibitory effect according to the treatment concentration of totarol alone or totarol in combination with DPG, respectively.

[0029] Figure 4 The results of comparing the antibacterial effects of totarol alone or in combination with DPG on Staphylococcus aureus are shown.

[0030] Figure 5 Shown are the results of comparing the antibacterial effects against Propionibacterium acnes according to totarol alone or totarol in combination with DPG.

[0031] Figure 6 The results are shown for confirming whether or not treatment with totarol and DPG in combination at different concentrations has cytotoxicity. DETAILED DESCRIPTION

[0032] Hereinafter, a more detailed description is given by way of examples. However, these examples are for illustration only, and the scope of the present invention is not limited to these examples.

[0033] Example 1: Confirmation of the stability of totarol according to solvent

[0034] After pure Totarol powder was put into different solvents and dissolved, the peak area of ​​Totarol was confirmed by using High Performance Liquid Chromatography (HPLC). The solvent used to confirm the stability is shown in Table 1 below, and stability is confirmed at low temperature (4°C), room temperature, high temperature (55°C) and daylight (SUN), and the results are shown in Table 2 below. As a result, it was confirmed that the stability of Totarol was the highest in DPG solvent.

[0035] [Table 1]

[0036]

[0037] [Table 2]

[0038]

[0039] Example 2: Confirmation of the SREBP-1c expression inhibitory effect of totarol alone or a combination of totarol and DPG

[0040] To evaluate the lipid synthesis inhibitory effect of totarol alone or a combination of totarol and DPG, the expression level of SREBP-1c in human immortalized sebocytes (SZ95) was measured. Differentiation of sebocytes in culture was induced by changing the composition of the culture medium.

[0041] Specifically, the cells were divided into 6-well plates and cultured, and culture medium and testosterone and linoleic acid for differentiation induction were added to each well and cultured for 24 hours, wherein fatty acid free bovine serum albumin, bovine pituitary extract, human epidermal growth factor (hEGF), alanyl glutamine (glutamax) and gentamicin (gentamicin) were added to the culture medium. After differentiation induction, washed with phosphate buffered saline (PBS), and single totarol or totarol and DPG combination were diluted in culture medium with 50ng / ml insulin-like growth factor (Insulin like growth factor, IGF) to make final concentrations of 1ppm (μg / ml) and 0.01% (totarol 1ppm) respectively, and added to each well. Then, further cultured for 24 hours, and extracted intracellular mRNA to synthesize cDNA. The synthesized cDNA was subjected to real-time polymerase chain reaction using target primers and SYBR green master mix as cyanine dye, thereby finally evaluating the gene expression level of SREBP-1c. The primers used in real-time PCR are shown in Table 3 below, and β-actin was used as the housekeeping gene.

[0042] [Table 3]

[0043]

[0044] Results, such as Figure 2As shown, it was confirmed that SREBP-1c overexpressed by IGF was significantly inhibited by treating totarol alone or totarol and DPG in combination to a final concentration of 1 ppm and 0.01%, respectively. In addition, it was confirmed that when totarol and DPG were treated in combination, an excellent SREBP-1c expression inhibitory effect was also exhibited compared to when totarol was treated alone.

[0045] Example 3: Inhibition of acne bacteria production by totarol alone or a combination of totarol and DPG

[0046] Propionibacterium acnes, which is known as a bacterium that forms acne, is a bacterium that overproliferates in hair follicles and sebaceous glands under anaerobic conditions and induces inflammation. In addition, it is known that Staphylococcus aureus is present in 30% of healthy adults. It is a general facultative anaerobic bacterium that causes suppurative inflammation of the skin and is a skin-harmful bacterium. In order to evaluate the antibacterial efficacy of totarol alone or a combination of totarol and DPG, a disc diffusion method was used. The Propionibacterium acnes (BF00034) strain and Staphylococcus aureus (BF00126) used in this experiment were purchased from the COSMAX microbiome library (CMB) and used.

[0047] Before the experiment, Propionibacterium acnes and Staphylococcus aureus strains were inoculated into liquid tryptic soy broth (Tryptic Soy Broth, TSB) culture medium, and the culture medium with 105 / mL was prepared for the strain. Sterilized cotton swabs were immersed in the culture medium, then streaked and smeared on solid tryptic soy agar (Tryptic Soy Agar, TSA) culture medium, and dried. Samples of totarol and totarol and DPG stock solutions to 10ppm, 25ppm and 50ppm diluted with sterile distilled water were soaked in a circular filter paper (Advantec Filter Paper, Toyo Roshi Kaisha Ltd, Japan) with a diameter of 6mm according to concentration, then sterile tweezers were used to place the sample on the culture medium, and cultured 48 hours under anaerobic conditions. As a control group, sterile distilled water or DPG was used, and the diameter of the clear zone was confirmed with the naked eye.

[0048] Results, such as Figure 4 and Figure 5 As shown, it was confirmed that when totarol was treated alone or in combination with DPG, it had antibacterial activity against Propionibacterium acnes and Staphylococcus aureus in a concentration-dependent manner, and it was confirmed that when totarol and DPG were treated in combination, a better antibacterial activity was exhibited compared to the case of totarol being treated alone.

[0049] Example 4: Sensory evaluation of compositions comprising totarol alone or a combination of totarol and DPG

[0050] With 5 test subjects as the object, the composition comprising a single totarol or a totarol and DPG combination was subjected to the following sensory evaluation. Specifically, 5 women aged between 20 and 30 years old were made to apply each composition (totarol 50ppm, including 1% totarol in the DPG raw material with 0.5% application of the composition) to the face including the nose periphery once in the morning and once in the evening during a week, and evaluated with the following evaluation criteria. In the sensory test, the three items such as pore reduction, blackheads and skin quality improvement were evaluated with higher preference, and the results are shown in Tables 4 to 6 below (5: very effective, 4: effective, 3: ordinary, 2: uncertain, 1: invalid).

[0051] [Table 4]

[0052]

[0053]

[0054] [Table 5]

[0055]

[0056] [Table 6]

[0057]

Claims

1. A cosmetic composition for improving skin condition, comprising totarol and a polyol, wherein: The improving skin condition is any one or more selected from the group consisting of inhibiting sebum, shrinking pores, improving blackheads and improving skin quality.

2. The cosmetic composition according to claim 1, characterized in that The polyol is one or more selected from the group consisting of dipropylene glycol, neopentyl glycol, diglycerol, glycerol, 1,3-butylene glycol, propylene glycol, propanediol, methylpropanediol, butylene glycol and sorbitol.

3. The cosmetic composition according to claim 2, characterized in that The polyol is dipropylene glycol.

4. The cosmetic composition according to claim 1, wherein The content of the totarol is 0.001 to 0.01 parts by weight relative to 100 parts by weight of the entire cosmetic composition.

5. The cosmetic composition according to claim 1, wherein The dosage form of the cosmetic composition is any one selected from the group consisting of emulsion, cream, lotion, solution, suspension, gel, patch, sheet mask, film, paste, spray, foam and cleansing water.

6. A composition for external use on skin for improving skin condition, comprising totarol and a polyol, wherein: The improving skin condition is any one or more selected from the group consisting of inhibiting sebum, shrinking pores, improving blackheads and improving skin quality.

7. The composition for external use on skin according to claim 6, characterized in that: The polyol is one or more selected from the group consisting of dipropylene glycol, neopentyl glycol, diglycerol, glycerol, 1,3-butylene glycol, propylene glycol, propanediol, methylpropanediol, butanediol and sorbitol.

8. The composition for external use on skin according to claim 7, characterized in that The polyol is dipropylene glycol.

9. The composition for external use on skin according to claim 6, wherein The content of the totarol is 0.001 to 0.01 parts by weight relative to 100 parts by weight of the entire cosmetic composition.

Images